Taxoids in combination chemotherapy for metastatic breast cancer

Anti-Cancer Drugs

Volumn 7, Issue SUPPL. 2, 1996, Pages 47-52

  Dieras, V ^a   Fumoleau, P ^b   Bourgeois, H ^a   Misset, J L ^c   Azli, N ^d   Pouillart, P ^a  

^a INSTITUT CURIE   (France)

^b CENTRE RENÉ GAUDUCHEAU   (France)

^c HÔPITAL PAUL BROUSSE   (France)

^d SANOFI   (France)

Author keywords

anthracyclines; docetaxel (Taxotere ); drug combinations; metastatic breast cancer; paclitaxel (Taxol ); vinorelbine (Navelbine )

Indexed keywords

ANTHRACYCLINE DERIVATIVE; DOCETAXEL; DOXORUBICIN; NAVELBINE; PACLITAXEL;

BREAST CANCER; CARDIOMYOPATHY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; FATIGUE; FEMALE; HUMAN; METASTASIS; MUCOSA INFLAMMATION; NEUTROPENIA; PRIORITY JOURNAL;

EID: 0029832490     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199608002-00012     Document Type: Conference Paper

References (33)

1. O'Shaughncssy JA, Fisherman JS, Cowan KH. Combination paclitaxel (Taxol®) and doxorubicin therapy for metastastic breast cancer [review]. Semin Oncol 1994; 2 (suppl 8): 19-23.
2. Hortobagyi GN, Holmes FA, Theriault RL, at al. Use of Taxol® (paclitaxel) in breast cancer. Oncology 1994; 51 (suppl 1): 29-32.
3. Dieras V, Marty M, Tubiana N, et al. Phase II randomized study of paclitaxel versus mitomycin in advanced breast cancer. Semin Oncol 1995; 22 (suppl 8): 33-39.
4. Van Oosterom AT, Schrijvers D. Docetaxel (Taxotere®), a review of preclinical and clinical experience. Part II: clinical experience. Anti Cancer Drugs 1995; 6: 356-368.
5. Ravdin P, Burris HA, Cook G, et al: Phase II trial docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 1995; 13: 2879-2885.
6. Valero V, Holmes FA, Walters RS, et al. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 1995; 13: 2886-2894.
7. Wilson WH, Berg SL, Bryant G, et al. Paclitaxel in doxorubicin-refractory or mitoxantrone refractory breast cancer: a phase I/II trial of 96-hour infusion. J Clin Oncol 1994; 12: 1621-1629.
8. Seidman AD, Barrett S, Hudis C, et al. Three hour Taxol infusion as initial (I) and as salvage (S) chemotherapy of metastatic breast cancer (MBC) [abstract]. Proc Am Soc Clin Oncol 1994; 13: A65.
9. Henderson IC, Allegra JC, Woodcock T, et al. Randomized trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol 1989; 7: 560-571.
10. Hahn SM, Liebman JE, Cool J, et al. Taxol® in combination with doxorubicin or etoposide. Possible antagonism in vitro. Cancer 1993; 72: 2705-2711.
11. Koechli OR, Sevin BU, Perras JP, et al. Characteristics of the combination paclitaxel plus doxorubicin in breast cancer cell lines analyzed with ATP-cell viability assay. Breast Cancer Res Treat 1993, 1994; 28: 21-7.
12. Bissery MC, Nohyneck G, Sanderink GJ, et al. Docetaxel (Taxotere®): a review of preclinical and clinical experience. Part 1: preclinical experience. Anti-Cancer Drugs 1995; 6: 339-368.
13. Bissery MC, Brignaud P, Lavell F. Preclinical profile of docetaxel (Taxotere®): efficacy as a single agent and in combination. Semin Oncol 1995; 22 (suppl 13):3-16.
14. Holmes FA. Update: the MD Anderson Cancer Center experience with paclitaxel in the management of breast carcinoma. Semin Oncol 1995; 22 (suppl 8): 9-15.
15. O'Shaughnessy JA, Cowan KH. Current status of paclitaxel in the treatment of breast cancer [review]. Breast Cancer Res Treat 1995; 33: 27-37.
16. Fisherman JS, McCabe M, Noone M, et al. Phase I study of Taxol®, doxorubicin, plus granulocyte-colony stimulating factor in patients with metastatic breast cancer. Monogr Natl Cancer Inst 1993; 15: 189-94.
17. Sledge GW, Robert N, Sparano JA, et al. Eastern Co-operative Oncology group studies of paclitaxel and doxorubicin in advanced breast cancer. Semin Oncol 1995; 22 (suppl 6): 15-8.
18. Gianni L, Munzone E, Capri G, et al. Paclitaxel by 3 hours infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumour efficacy and cardiac effects in a dose finding and sequence finding study. J Clin Oncol 1995; 13: 2688-2699.
19. Gehl J, Ejlersen B, Boesgaard M, et al. Efficacy and toxicity of combined doxorubicin and paclitaxel in metastatic breast ancer (preliminary results) [abstract 192]. Ann Oncol 1994; 5 (suppl 8).
20. Berg SL, Cowan KH, Balis FM, et al. Pharmacokinetics of Taxol and doxorubicin administered alone and in combination by continuous 72-hour infusion. J Natl Cancer Inst 1994; 86: 143-145.
21. Holmes FA. Combination chemotherapy with Taxol® (paclitaxel) in metastatic breast cancer. Ann Oncol 1994; 5 (suppl 6): S23-27.
22. Spielman M, Gatimel G, Kayitalire L, et al. Taxol® (paclitaxel) and Farmorubicin (epirubicin) in metastatic breast cancer: preliminary results of a phase I study [abstract 370]. Eur J Cancer 1995; 31A (suppl 5).
23. Luck HJ, Thomssen C, du Bois A, et al. Phase II study of paclitaxel and epirubicin as first line therapy in patients with metastatic breast cancer [abstract 304]. Breast Cancer Res 1996; 37 (suppl).
24. Dieras V, Gruia G, Pouillart P, et al. A phase I study of the combination of docetaxel and in first line chemotherapy treatment of metastatic breast cancer: preliminary results [abstract 313]. Breast Cancer Res 1996; 37 (suppl)
25. Potier P. The synthesis of Navelbine, prototype of a new series of vinblastine derivatives. Semin Oncol 1989; 6 (suppl 4): 2-4.
26. Fumoleau P, Delgado FM, Delozier T, et al. Phase II trial of weekly intravenous vinorelbine in first line advanced breast cancer chemotherapy. J Clin Oncol 1993; 11: 1245-1252.
27. Weber BL, Vogel C, Jones S, et al. A United States multicenter phase II trial of Navelbine in advanced breast cancer. J Clin Oncol 1995; 13: 2722-2730.
28. Fellous A, Ohayon R, Vacassin T, et al. Biochemical effects of Navelbine on tubulin and associated proteins. Semin Oncol, 1989; 16 (suppl 4): 9-14.
29. Parness J, Horwitz SB. Taxol® binds to polymerized tublin in vitro. J Cell Biol 1981; 91: 479-87.
30. Ibrahim N, Hortobagyi GN, Valero V, et al. Phase I study of vinorelbine (Navelbine) and paclitaxel by simultaneous 3-hour infusion for untreated metastatic breast cancer. Proc Ann Meet Am Assoc Cancer Res 1995; 36: A1443.
31. Ibrahim NK, Hortobagyi GN, Valero V, et al. Phase I study of vinorelbine (Navelbine) and paclitaxel (Taxol®) by simultaneous 3-hour infusion, with G-CSF support, for untreated metastatic breast cancer [abstract 107]. Breast Cancer Res Treat 1996; 37.
32. Chang A, Garrow G, Mines J, et al. Pilot study of vinorelbine (Navelbine) and paclitaxel (Taxol®) in patients with refractory breast cancer [abstract 315]. Breast Cancer Res 1996; 37 (suppl).
33. Fumoleau P, Delecroix V, Gentin M, et al. Docetaxel in combination with vinorelbine as first-line chemotherapy in patients with metastatic breast cancer: phase I dose-finding study [abstract 938]. Eur J Cancer 31A, (suppl 5). S195.